Stoke Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Stoke Therapeutics, Inc. (Nasdaq: STOK) on March 23, 2026. The filing addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Dismissal of Previous Auditor: On March 23, 2026, the Audit Committee dismissed KPMG LLP as the independent registered public accounting firm.
- Audit History: KPMG's reports for fiscal years ended December 31, 2025, and 2024, contained no adverse opinions, disclaimers, or qualifications. There were no disagreements or reportable events between the Company and KPMG during these periods or the interim period through March 23, 2026.
- Appointment of New Auditor: On March 23, 2026, the Audit Committee appointed Ernst & Young LLP (EY) as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Consultation with New Auditor: The Company confirms no consultations with EY regarding accounting principles, financial statement disclosures, or auditing scope during the two most recent fiscal years or the interim period.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on business outlook, or specific risk factors beyond the standard disclosure of the auditor change. The company has filed a letter from KPMG (Exhibit 16.1) stating their agreement with the disclosures made in this report.
Investor Verification Checklist
- Verify the reasons for the auditor change by reviewing the full text of the KPMG letter filed as Exhibit 16.1.
- Confirm the effective date of the transition from KPMG to EY for the 2026 fiscal year.
- Review subsequent filings (e.g., 10-K or 10-Q) for the first financial statements audited by EY to assess any changes in accounting treatment or disclosures.
- Monitor for any future 8-K filings regarding disagreements or reportable events that may arise during the transition period.